Navigation Links
Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
Date:3/10/2008

- Formulation Has Potential to Address Large Acute Pain Prescription Drug

Market -

LAVAL, QC, March 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has begun enrolling patients in its Phase III clinical trial for its twice-daily, tramadol-acetaminophen combination product (study 06CCL3-001).

"Tramadol-acetaminophen combination products have become widely prescribed based on their ability to provide the analgesic potency of tramadol and the rapid efficacy of acetaminophen, as well as their use in treating a broad spectrum of pain types," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Our formulation has the potential to be the first twice-daily tramadol-acetaminophen product, as well as to compete in the broader acute pain prescription drug market globally. Accordingly, it would be an excellent complement to our once-daily tramadol product for the treatment of persistent pain."

Currently marketed tramadol-acetaminophen combination products must be administered four- to six-times per day. Labopharm believes that by metering the release of both tramadol and acetaminophen from a single tablet using its Contramid(R) controlled-release technology, its formulation has the potential to offer enhanced patient compliance through twice-daily administration, as well as a potentially improved side effect profile. More importantly, based on its potential potency, efficacy, safety and convenience, the Company's novel formulation of tramadol-acetaminophen could be well positioned as an alternative to other prescription products for the treatment of mild to moderate acute pain, including mild-opioids, tramadol, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs) and combination forms of these products.

Study 06CCL3-001 is a multi-centre, randomized, double-blind, parallel-arm study that will compare the efficacy and safety o
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)..., Va., Nov. 21 The Gene...e following statement today from,GPhA President a... Commission,(FTC) roundtable on "Emerging Health ...he mere fact that the FTC is conducting this round...suring that consumers have access to safe and,aff...
(Date:11/21/2008)...N, W.Va., Nov. 21 New r... whether a smokeless, spitless tobacco product aim...hers have found that RJ Reynolds, Camel Snus - tou...ion - contains surprisingly high levels of nicotin...han most other snuff products," said Bruce Adkins ...
(Date:11/21/2008)...LAKES, N.J., Nov. 21 Tod...dical intervention in treating 88 percent of patie...of Americans treated for a chronic condition accou...g and 75 percent of all medical costs. A propriet...by Medco Health Solutions, Inc. (NYSE: MHS ) sig...
(Date:11/21/2008)...ov. 21 In a statewide survey, 33 p...stitute for Surgery at Presbyterian Hospital of Da...nnual listing of " Super Doctors ." , , Eac...h Key Professional Media, Inc. to survey more than...Texas to ask, "If you needed medical care, which d...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...n 10 unfilled posts in Queensland is causing worry...rease.// The posts have been vacant for some four ...been put at risk. Numbers released by Queensland ... 150 positions being unfilled across the district ...
...se gasses which result in global warming may resul...hanges across the world. The chemical composition ... creatures were // analyzed by the researchers Ric...ipps Institution of Oceanography at the University...
...thousand women in India work under unsanitary and ...try towards preserving the slice and shell marine ... Health (NIOH) based in Ahemedabad conducted a stu... women age prematurely. "Women working in fish p...
... a bad side to the WinRho drug, used for treating ...nal Inc. and Cangene Corp, the drug has a tendency... The Winrho drug has been in use in the United Sta... bleeding disorder called Immune Thrombocytopenic ...
Other Medicine News:Health News:Earth Will Feel The Impact Of Global Warming 2Health News:Unregulated Fish Industry Harms Health Of Women 2
(Date:11/19/2008)...RANCISCO, Nov. 19 Posit Science Co...nce at the Society for Neuroscience,Annual Confer...ognitive,training may benefit Baby Boomers. The ... Program (TM) uses adaptive exercises that target ... designed to drive generalized,improvements in co...
(Date:11/19/2008)...ude scientists report basic findings on critical e...ow to better treat an array of disorders , , ...-- Scientists at St. Jude Children,s Research Hos...one of the body,s enzyme workhorses called calpain...rs, calpains function in many cellular processes, ...
(Date:11/19/2008)...gers $5 Million Payment from Roche- , , MON...ory Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... for its Phase 2 trial of R3487/MEM 3454, its lead...impairment associated with schizophrenia (CIAS). ...se 2 trial, triggering a $5.0 million payment from...
(Date:11/18/2008)...RN, Pa., Nov. 18 Arlington Medical...telligence for the pharmaceutical and diagnostic,... CSL Behring,s Privigen was,sold in the U.S. duri...st,brand of intravenous immune globulin (IVIG) an... is a product created from the blood plasma of tho...
Breaking Medicine Technology:New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Westaim terminates reorganization agreement and cancels shareholders meeting 28784 1 TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 28780 1 TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 28780 2K State Veterinarian Discusses Treating Dogs With Cushings Disease 28776 1K State Veterinarian Discusses Treating Dogs With Cushings Disease 28776 2Maternal obesity can program fetal brain to induce adult onset obesity 28773 1Maternal obesity can program fetal brain to induce adult onset obesity 28773 2
...NESS WIRE)--May 8, 2007 - King,Pharmaceuticals, In... a Phase III clinical trial for its ALTACE(R) (ram...ted at the American,Society of Hypertension,s Twen... Saturday, May 19, 2007 at the Hyatt Regency Hotel...be available for,review from 10 AM to 6 PM CDT. Th...
...(BUSINESS WIRE)--May 8, 2007 - AVANIR,Pharmaceutic...n the,efficacy, safety and improvements in patient...heral neuropathic (DPN) pain treated,with the inve...inidine) will be presented in two scientific poste...thic Pain, being held in,Berlin, Germany on June 7...
Other Medicine Technology:King Pharmaceuticals Announces Plan to Present Results from Phase,III Clinical Trial Evaluating ALTACE as Monotherapy and in,Combination with Hydrochlorothiazide at the American Society of,Hypertension Annual Meeting 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium.
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm
Straight Iris Scissors; ring handle; 28mm from mid screw to tip; sharp tips; Overall length 110; Also available in 100mm overall length; Stainless Steel
The SURPASS Perfusion Catheter is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The SURPASS
Medicine Products: